INVENIO THERAPEUTICS INC

Biotech · Defunct

CTX1, a small molecule inhibitor of HdmX that disrupts p53 interactions to induce cancer cell death

Grants
$2.3M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase II · Original Phase 1 Title: Identifying Small Molecule Inhibitors of HdmX using Cell-based Screening Revised Title: Development of a Novel HdmX Inhibitor for Leukemia$775,796
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase II · Original Phase 1 Title: Identifying Small Molecule Inhibitors of HdmX using Cell-based Screening Revised Title: Development of a Novel HdmX Inhibitor for Leukemia$1,493,586
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1303Maze Therapeutics——
1304LUNG THERAPEUTICS INC——
1305Immunomedics——
1306INVENIO THERAPEUTICS INC——
1307CONFOMETRX, INC.——
1308Cavatar LLC——
1309COARE BIOTECHNOLOGY, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Small Molecule Securinine And Norsecurinine Analogs And Their Use In Cancers Inflammatory Diseases And Infectionsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.